The global demand for Prothrombin Complex Concentrate Market is presumed to reach the market size of nearly USD 910.94 Million by 2032 from USD 855.51 Million in 2023 with a CAGR of 0.7% under the study period 2024-2032.
Prothrombin complex concentrate is a hemostatic blood product used as medication. It is made up of blood clotting factors II, IX, X, and sometimes factor VII. This concentrate has the ability to reverse the effects of warfarin and other vitamin K anticoagulants. It is used in significant bleeding cases in people with coagulopathy or when such patients undergo an emergency operation treatment. It is also used in people with a deficiency of one of the clotting factors because of congenital, liver disease, or hemophilia. It is administered using a slow injection directly into the human vein. It is produced by the ion-exchange chromatography of the cryoprecipitate supernatant of large plasma pools and antithrombin and factor XI removal.
MARKET DYNAMICS
The increased prevalence of bleeding disorders and eased government approval for innovative medical therapies are few driving factors favoring the market growth. The rising demand for PCC for treating unwanted excessive bleeding during surgical procedures due to its high clinical efficiency will benefit the market's growth. The growing use of warfarin therapy and the high efficiency of prothrombin complex concentrates in rapidly reversing coagulopathy in patients with warfarin-related intracranial hemorrhage will enhance the market growth. Increased investments in the research and development of new drugs to treat blood clotting disorders and improving healthcare infrastructure will be a market booster. Lack of awareness and the side effects of these medications can have a burdening impact on market growth.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Prothrombin Complex Concentrate. The growth and trends of Prothrombin Complex Concentrate industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Prothrombin Complex Concentrate market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Product
3-factor PCC
4-factor PCC
By Application
Acquired Coagulation Factor Deficiency
Congenital Coagulation Factor Deficiency
Others
By End-use
Hospital & Ambulatory Surgical Centers
Specialty Clinics
Others
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Prothrombin Complex Concentrate market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Prothrombin Complex Concentrate market include CSL, Octapharma AG, Kedrion, Takeda Pharmaceutical Company Limited., Taibang Biological Group Co. Ltd., Sanquin, Grifols, S.A., Biotest AG, Abeona Therapeutics Inc., Insud Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
10. COMPANY PROFILES OF PROTHROMBIN COMPLEX CONCENTRATE INDUSTRY
10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. CSL
10.3.1 Company Overview
10.3.2 Company Revenue
10.3.3 Products
10.3.4 Recent Developments
10.4. Octapharma AG
10.4.1 Company Overview
10.4.2 Company Revenue
10.4.3 Products
10.4.4 Recent Developments
10.5. Kedrion
10.5.1 Company Overview
10.5.2 Company Revenue
10.5.3 Products
10.5.4 Recent Developments
10.6. Takeda Pharmaceutical Company Limited.
10.6.1 Company Overview
10.6.2 Company Revenue
10.6.3 Products
10.6.4 Recent Developments
10.7. Taibang Biological Group Co. Ltd.
10.7.1 Company Overview
10.7.2 Company Revenue
10.7.3 Products
10.7.4 Recent Developments
10.8. Sanquin
10.8.1 Company Overview
10.8.2 Company Revenue
10.8.3 Products
10.8.4 Recent Developments
10.9. Grifols
10.9.1 Company Overview
10.9.2 Company Revenue
10.9.3 Products
10.9.4 Recent Developments
10.10. S.A.
10.10.1 Company Overview
10.10.2 Company Revenue
10.10.3 Products
10.10.4 Recent Developments
10.11. Biotest AG
10.11.1 Company Overview
10.11.2 Company Revenue
10.11.3 Products
10.11.4 Recent Developments
10.12. Abeona Therapeutics Inc.
10.12.1 Company Overview
10.12.2 Company Revenue
10.12.3 Products
10.12.4 Recent Developments
10.13. Insud Pharma
10.13.1 Company Overview
10.13.2 Company Revenue
10.13.3 Products
10.13.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies